Results 221 to 230 of about 254,141 (317)

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair   +14 more
wiley   +1 more source

Examining Self-Reported Executive Function and Its Relationship to Patient-Reported Outcomes and Disease-Related Factors in Youth With Childhood-Onset Lupus: A Cross-Sectional Study. [PDF]

open access: yesACR Open Rheumatol
El Tal T   +12 more
europepmc   +1 more source

The role of sulfhydryl groups in permitting transformation and DNA binding of the glucocorticoid receptor.

open access: hybrid, 1987
W Tienrungroj   +6 more
openalex   +1 more source

Dexamethasone regulates gene expression in chondrocytes through MKP-1 and downregulates cholesterol hydroxylases CH25H and CYP7B1. [PDF]

open access: yesInflamm Res
Lehtola T   +7 more
europepmc   +1 more source

The preterm labor associated ADAMTS2 gene is induced by glucocorticoids

open access: green, 2018
Alasdair Jubb   +3 more
openalex   +2 more sources

Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting –Adjusted Comparison to a Historical Control Group Treated With Belimumab

open access: yesArthritis &Rheumatology, EarlyView.
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo   +15 more
wiley   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy